About: Efficacy of injectable toltrazuril-iron combination product and oral toltrazuril against early experimental infection of suckling piglets with Cystoisospora suis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy of injectable toltrazuril-iron combination product and oral toltrazuril against early experimental infection of suckling piglets with Cystoisospora suis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy of injectable toltrazuril-iron combination product and oral toltrazuril against early experimental infection of suckling piglets with Cystoisospora suis
Creator	Joachim, Anja Shrestha, Aruna Hodžić, Adnan Hinney, Barbara Guerra, Nicolas Karembe, Hamadi Sperling, Daniel
Source	Medline; PMC
abstract	BACKGROUND: Toltrazuril is frequently administered for the metaphylactic control of piglet cystoisosporosis. In a previous study, the efficacy of parenteral toltrazuril (45 mg/piglet, Group Forceris®) applied on the 2nd day of life (dol), and of oral toltrazuril (20 mg/kg of body weight, Group Baycox®) applied on the 4th dol was evaluated in an experimental model with Cystoisospora suis infection on the 3rd dol (late infection, LI). In a follow-up study, efficacy and safety were evaluated against infections with C. suis on the 1st dol (early infection, EI). Parameters included oocyst excretion and faecal consistency, body weight development, bacteriological examinations and animal health. RESULTS: All control piglets (n = 12) shed oocysts and had diarrhoea, while parasite excretion was completely suppressed in both treatment groups (n = 13 each) and diarrhoea was reduced to a single animal (Forceris® group), resulting in significant differences for these parameters between the treated groups and the controls without significant differences among the treatment groups. No treatment-related adverse events were noted. Body weight gain was reduced in the control group during the acute phase of infection, resulting in significantly lower body weight on the 15th dol. Sows and piglets shed high numbers of Escherichia coli. Clostridium perfringens type A was only detected in low amounts in pooled litter samples. In comparison to the LI study oocyst shedding was more intense in the control animals in EI, while diarrhea was more frequent in LI. In both infection models a high efficacy of toltrazuril in the control of parasitological and clinical outcomes of experimental C. suis infection could be demonstrated. Since in the LI study high numbers of Cl. perfringens type A were detected, it is hypothesized that colonization with these opportunistic pathogens has synergistic effects with C. suis and may explain variable clinical outcomes in untreated animals as well as the sporadic occurrence of diarrhea in toltrazuril-treated piglets. CONCLUSIONS: Parenteral and oral toltrazuril administered on the 2nd or 4th dol is safe and effective against experimental infections with C. suis on the 1st to 3rd dol. The clinical outcome of experimental infections seems influenced by bacterial coinfections.
has issue date	2019-05-28(xsd:dateTime)
bibo:doi	10.1186/s13071-019-3527-3
bibo:pmid	31138327
has license	cc-by
sha1sum (hex)	e6582d6d45bf69e0713bb09195f1c3226bb813a7
schema:url	https://doi.org/10.1186/s13071-019-3527-3
resource representing a document's title	Efficacy of injectable toltrazuril-iron combination product and oral toltrazuril against early experimental infection of suckling piglets with Cystoisospora suis
has PubMed Central identifier	PMC6540551
has PubMed identifier	31138327
schema:publication	Parasit Vectors
resource representing a document's body	covid:e6582d6d45bf69e0713bb09195f1c3226bb813a7#body_text
is schema:about of	named entity 'body weight' named entity 'Parameters' named entity 'evaluated' named entity 'Cystoisospora' named entity 'oral' named entity 'piglets' named entity 'GROUP' named entity '3RD' named entity 'EVALUATED' named entity 'INCLUDED' named entity 'MG%' named entity '2ND' named entity 'EXAMINATIONS' named entity 'efficacy' named entity 'Toltrazuril' named entity 'infection' named entity 'infection' named entity 'toltrazuril' named entity 'dol' named entity 'animal health' named entity 'infection' named entity 'infection' named entity 'piglet' named entity 'Toltrazuril' named entity 'infection' named entity 'toltrazuril' named entity 'body weight' named entity 'follow-up' named entity 'Cystoisospora' named entity 'parenteral' named entity 'toltrazuril' named entity 'infection' named entity 'parasite' named entity 'oocyst' named entity 'diarrhoea' named entity 'infection' named entity 'piglet' named entity 'aetiology' named entity 'body weight' named entity 'toxin' named entity 'enteritis' named entity 'body weight' named entity 'infection' named entity 'Cystoisospora' named entity 'C. suis' named entity 'C. suis' named entity 'E. coli' named entity 'oocysts' named entity 'parasite' named entity 'viral infections' named entity 'infection' named entity 'excretion' named entity 'control group' named entity 'coccidia' named entity 'tissue damage' named entity 'necrotic enteritis' named entity 'iron-deficiency anaemia' named entity 'faeces' named entity 'Cystoisospora' named entity 'oocyst' named entity 'iron' named entity 'control group' named entity 'Kruskal-Wallis test' named entity 'diarrhoea' named entity 'E. coli' named entity 'oocysts' named entity 'toltrazuril' named entity 'diarrhoea' named entity 'oocysts' named entity 'weight gain' named entity 'oocyst' named entity 'autofluorescence' named entity 'Virbac' named entity 'parasite' named entity 'enteropathogens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software